Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LMN-101 in Healthy Volunteers
NCT04098263Phase 1Completed
- Sponsor
- Lumen Bioscience
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LMN-101 in Campylobacter jejuni infection (4 arms), sponsored by Lumen Bioscience. Primary endpoint: Count of Participants With Adverse Events. Started Nov 2019; status: completed.
02
Drugs
LMN-101
03
Conditions
Campylobacter jejuni infection
Beyond the preview
Go deeper on NCT04098263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098263.